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Introduction 
Development of transgenic animals has become technically more feasible over the 
past several decades creating opportunities for the genetic modification of numerous 
species.  This dramatic expansion in the number of genetic modifications in pigs, in 
particular, is due to the advancement of molecular techniques that facilitate genetic 
modification as well as their agricultural importance and physiological characteristics, which 
make them an ideal model to conduct translational biomedical research.  Genetic 
modification of pigs can address both basic and applied research questions with implications 
for agriculture and medicine. 
 
Pig Biomedical Utility 
Pigs are increasingly being utilized as biomedical models.  Even without genetic 
modification, pigs have been used by many investigators to model cardiovascular 
physiology, reproduction, skin physiology, respiratory function and infectious disease 
(Lunney 2007; Prather et al. 2008; Yang and Ross 2012).  However, precise manipulations of 
pig genomes allows the generation of pig models for specific genetic diseases.  Strategies for 
introducing genetic modifications into the swine genome have accelerated their utility as 
biomedical models by facilitating rapid development of numerous transgenic pig models. 
Multiple approaches have been explored to create transgenic animals that have been 
previously characterized with respect to the strengths and weaknesses of each approach 
(Ross and Prather 2010; Yang and Ross 2012). 
 
Strategies for Developing Transgenic Pigs 
Milestones achieved in the development of transgenic pigs often follows shortly 
after similar achievements in mice.  For example, the first transgenic mice were developed 
over 30 years ago (Brinster et al. 1981; Costantini and Lacy 1981; Gordon et al. 1980; 
Wagner et al. 1981) and the technique was further refined to include utilization of 
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embryonic stem (ES) cells coupled with homologous recombination to created mice with 
targeted genetic modifications (Doetschman et al. 1987; Thomas and Capecchi 1987).  
Pronuclear injection of linearized DNA into the single cell zygote pronuclei, however, 
is not an efficient process.  Nevertheless, not long after publication of the first knockout 
mice, the technique was used to produce transgenic pigs (Bleck et al. 1998; Hammer et al. 
1985; Petters et al. 1997; Vize et al. 1988) and other large animal models (Bondioli et al. 
1991; Wang et al. 2002).  Sperm mediated transgenesis (SMTG) relies on the ability of 
mammalian sperm to bind DNA consequently serving as the vehicle through which 
exogenous DNA constructs can be delivered into the newly created zygote.  SMTG can occur 
via insemination or intracytoplasmic sperm injection (ICSI ) (Kurome et al. 2007; Kurome et 
al. 2006; Lavitrano et al. 1997; Pereyra-Bonnet et al. 2008; Perry et al. 1999; Webster et al. 
2005).  In the case of oocyte transduction, AAV vectors integrate into metaphase 
chromosomes while the oocyte is arrested in metaphase II of meiosis.  The strategy  was 
first accomplished in cattle (Chan et al. 1998) and later, a similar approach in pigs was used 
to create the first eGFP transgenic pigs (Cabot et al. 2001). 
While those strategies have been useful in creating transgenic pigs, the most 
commonly utilized approach is the genetic modification of a somatic cell followed by nuclear 
transfer.  Since the birth of Dolly in 1996 (Wilmut et al. 1997) somatic cell cloning of other 
large animal species (Baguisi et al. 1999; Cibelli et al. 1998; Galli et al. 2003; Jang et al. 2007; 
Woods et al. 2003; Yin et al. 2008) (Oh et al. 2008), including pigs (Polejaeva et al. 2000) has 
been widely used .   
 
Genetic Modification followed by Somatic Cell Nuclear Transfer  
Generation of cloned transgenic pigs through nuclear transfer requires the utilization 
of a donor cell whose genome can be effectively remodeled and reprogrammed to complete 
term gestation.  Importantly, that cell type must be capable of being genetically modified 
prior to SCNT.  While numerous cell types in pigs have been successfully used (Beebe et al. 
2007; Brunetti et al. 2008; Hornen et al. 2007; Hyun et al. 2003; Kurome et al. 2008; Lai et al. 
2002a; Lai et al. 2002b; Tomii et al. 2005), we have had success primarily with fetal 
fibroblasts (Ross et al. 2012; Ross et al. 2010; Zhao et al. 2009). Fetal fibroblasts are used as 
they generally do not senesce until after ~30 days making genetic engineering and selection 
within their lifespan feasible.  Efficient generation of genetic modifications in donor cell 
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genome relies not only on the targeting/integration strategy but also on the efficient 
introduction of the exogenous DNA into the potential donor cell and subsequent selection 
of stable integrated cells.  In pigs, a variety of methods have been quite effective at 
introducing exogenous DNA into the somatic cell, including lipid based delivery (Hyun et al. 
2003; Lee et al. 2005), viral delivery (Rogers et al. 2008), and electroporation (Arat et al. 
2001; Ramsoondar et al. 2003; Ross et al. 2010).  These strategies have been used by us and 
others to create genetically modified pigs that are contributing to biomedical research 




Using some of the above mentioned approaches we have developed a miniature 
swine model of retinitis pigmentosa (RP) (Ross et al. 2012).  In this case, we utilized the 
human rhodopsin gene containing the P23H mutation, the most common mutation in the 
rhodopsin gene resulting in RP in humans.  The construct was linearized, and electroporated 
into the cells using the strategies we developed for transfection of pig fetal fibroblasts (Ross 
et al. 2010).  The result was the production of six founder P23H miniature pigs. Each of the 
founders demonstrated a unique disease phenotype with respect to disease onset and 
progression. These differences in phenotype are likely the result of copy number variation 
of the integrated transgene and the different integration sites in the genome between the 
founders, as demonstrated by in in situ hybridization and southern blot analysis. This model 
is now being utilized as a translational research model for investigators working towards 
developing strategies to mitigate the devastating effects of RP in humans. 
Muscular Dystrophy 
While genetic modifications to pigs can be made to create novel and useful 
biomedical models of disease, some can be serendipitously discovered, as was the case with 
the discovery of a pig model of Becker muscular dystrophy (BMD) by a research group at the 
USDA and its subsequent characterization.  BMD, caused by a dystrophin insufficiency, is a 
progressive muscle disease where over time whole muscles become more fibrotic and less 
functional.  It is related to the more severe Duchenne muscular dystrophy (dystrophin 
deficiency), which is a 100% fatal disease due to respiratory or cardiac failure in the mid-20s.  
BMD patients may have disease phenotype that closely matches that of DMD or a milder 
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phenotype, depending on the causative mutation.  A line of pigs that died at a high rate 
during transport was found to have a mutation in the dystrophin gene and a 60-90% 
reduction in dystrophin protein abundance (Nonneman et al. 2012).  In conjunction with this 
group, we found recently that this mutation led to muscle injury in the diaphragm and 
longissimus but not the psoas at only eight weeks of age.  This is important because the 
diaphragm and longissimus are used far more frequently than the psoas in penned animals 
pointing toward a use-dependent disease severity.  Also, dystrophin insufficiency led to a 
failure of the dystrophin-glycoprotein complex to correctly assemble, which is also 
consistent with the disease observed in humans.  Our next step will be to determine the 
extent to which dystrophin insufficiency leads to muscle injury and loss of muscle function 
as the disease progresses.   
 
Conclusion 
 Pigs are and will continue to be utilized as biomedical research models.  
Development of strategies to improve the efficiency of genetic modifications, such as the 
utilization of zinc finger nucleases and Tal effector nucleases will further enable precise 
genetic manipulation of pigs to expand their utility as biomedical models (Carlson et al. 
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